Proactive monitoring of drug–drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer

HIGHLIGHTS

• What: The authors aimed to include as many patients using a DOAC-SMI combination as possible between December 2021 and August 2023. The potential of clinically relevant DDIs between SMIs and DOACs included in this study are previously described in a number of reviews . Although the number of patients with DOAC concentrations outside the expected range did not change upon addition of an SMI (i.e., in Group 1), 71.4% (5/7) of the included patients in this analysis had a DOAC Ctrough and/or Cpeak decrease or increase of more than 50% after SMI initiation . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.